WorldUpstart, LLC recently announced the launch of the Winter 2024 U.S. Market Gateway Accelerator, an 8-week program designed to assist international Life Science and MedTech companies in expanding their operations in the United States. The program, which began on February 5, 2024, and culminates with a visit to Philadelphia on April 8-9, 2024, features eleven companies from Canada, France, Israel, Poland, the UK, and Ukraine.
The selected companies were chosen from a diverse pool of applicants, including hundreds of startups and established companies in the Digital Health, Drug Development, and Medical Device sectors from around the world. These companies are now poised to make their mark in the U.S. healthcare industry with the support and guidance offered by the U.S. Market Gateway Accelerator.
Karina Sotnik, Founder and CEO of WorldUpstart, emphasized the challenges and opportunities that come with expanding into the U.S. market. She stated, “U.S. Market expansion brings tremendous opportunities but also presents significant challenges. Companies often encounter blind spots when attempting to do it alone. With advice from top experts and mentoring from trusted industry veterans, our soft-landing program offers companies a tailored strategic roadmap to not only enter but also to scale within the U.S. market successfully.”
The Winter 2024 Cohort includes a diverse group of companies with innovative solutions and products aimed at transforming the healthcare industry. Some of the companies featured in the program include CheckEye, Diagnoly, DragOnFlow Systems, Figura Analytics, Hip Impact Protection (HIP), MediSensonic, Preventx, QiiQ Healthcare, Rostra Therapeutics, Unlimited Robotics, and Vivid Health.
WorldUpstart has established itself as a key player in assisting international companies in Life Science, MedTech, and Digital Health as they prepare to enter the U.S. market. The U.S. Market Gateway Accelerator has already proved successful in helping companies create a roadmap for expansion and connect with the right players, partners, and investors. In the past three years, the program has graduated 64 companies from 18 countries, with 25 now operating in the U.S. and eight with FDA-approved products and services.
The success rate of WorldUpstart’s accelerator program participants stands out at 40%, compared to the 20% success rate typically seen among international companies entering the U.S. market. The program has more than doubled the participant’s chances of success, creating a paradigm shift in their market entry strategy.
Overall, the Winter 2024 U.S. Market Gateway Accelerator offers a comprehensive and strategic approach to helping international companies navigate the U.S. healthcare industry and establish a successful presence in the market. With a commitment to mentoring, guidance, and support, WorldUpstart is paving the way for international companies to thrive in the U.S. healthcare market.
Source link
